Aimei Health files Form 12b-25 for late 2025 10-K

Aimei Health Technology Co., Ltd notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report could not be completed before the due date.

Rhea-AI Filing Summary

Aimei Health Technology Co., Ltd notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report could not be completed before the due date. The company submitted a Form 12b-25 notification dated April 1, 2026 and invoked Rule 12b-25 relief.

The filing states the company checked the Rule 12b-25(b) boxes that describe (a) the reasons required more effort, and (b) the intent to file within the calendar extension period provided by the rule. Contact listed: Junheng Xie, CEO, phone +86 13758131392.

Insights

Compliance Officer

Form 12b-25 reports a routine late 10-K due to incomplete review.

The notification states the annual report for the fiscal year ended December 31, 2025 was not completed before the prescribed due date because the review could not be finished in time. The company invoked Rule 12b-25 and indicated it will use the calendar extension provided by that rule.

Key items to watch in subsequent filings are the timely filing of the complete Form 10-K within the Rule 12b-25 extension and any disclosure in the 10-K about causes or material changes to results; timing is set by the rule's calendar-day extensions.

Key Figures

Fiscal period end: December 31, 2025 Form 12b-25 signature date: April 1, 2026 Contact phone: +86 13758131392

3 metrics

Fiscal period end December 31, 2025 Period Ended shown on Form 12b-25

Form 12b-25 signature date April 1, 2026 Date the notification was signed by the CEO

Contact phone +86 13758131392 Telephone number listed for Junheng Xie on the form

Key Terms

Form 12b-25, Rule 12b-25(b), Transition Report

3 terms

Form 12b-25 regulatory

"We could not timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2025"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

Rule 12b-25(b) regulatory

"The subject annual report ... will be filed on or before the fifteenth calendar day following the prescribed due date"

Transition Report regulatory

"Transition Report on Form 10-K -------------------------------------"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Aimei Health's (AFJK) Form 12b-25 mean?

It formally notifies the SEC that the company could not file its annual report on time. The notice states the review of the Form 10-K for the year ended December 31, 2025 was incomplete and relief under Rule 12b-25 was requested.

When was the Form 12b-25 for AFJK signed?

The Form 12b-25 was signed on April 1, 2026. That date is shown on the notification and indicates when the company certified the late-filing reason to the SEC.

Who signed the late filing notice for Aimei Health (AFJK)?

The notice was signed by Junheng Xie, identified as Chief Executive Officer and Director. A phone contact of +86 13758131392 is provided on the form.

Does Form 12b-25 confirm when the 10-K will be filed?

No, it does not give a specific filing date. The filing cites Rule 12b-25 and the company’s intent to use the rule’s calendar extension to complete and file the Form 10-K.

Does the notification say results will materially change?

The form indicates the company answered the question about significant changes in results with No. It does not attach narrative or quantitative changes to be reflected in the 10-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

	NOTIFICATION OF LATE FILING	SEC FILE NUMBER
		001-41880
		CUSIP NUMBER
		G01341109

(Check One): ☒ Form 10-K ☐  Form 20-F ☐ Form 11-K   ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: December 31, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q

For the Transition Period Ended: _______________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any

information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

Aimei Health Technology Co., Ltd

Full Name of Registrant

Former Name if Applicable

10 East 53rd Street, Suite 3001

Address of Principal Executive Office (Street and Number)

New York, NY 10022

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

We could not timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report on Form 10-K could not be completed in a timely fashion prior to the due date of the report.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Junheng Xie		+86		13758131392
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).	☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?	☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Aimei Health Technology Co., Ltd

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 1, 2026	By:	/s/ Junheng Xie
	Name:	Junheng Xie
	Title:	Chief Executive Officer and Director

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).